NCT02740179View on ClinicalTrials.gov

Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

March 17, 2022

Study Completion Date

March 17, 2022

Conditions
HIV
Interventions
DRUG

Eplerenone

Eplerenone 50mg by mouth twice daily

DRUG

Placebo

Placebo by mouth twice daily

BEHAVIORAL

Lifestyle Modification

Counseling regarding diet and healthy activity

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT02740179 - Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study) | Biotech Hunter | Biotech Hunter